Elderly patients with type 2 diabetes who received linagliptin, a dipeptidyl peptidase-4 inhibitor, showed significant reductions in blood glucose levels compared with those treated with a placebo, according to a study in The Lancet. After 24 weeks on linagliptin, the mean change from baseline in A1C was -0.64%. The safety and tolerability profile was comparable to that of the placebo.

Related Summaries